ObjectiveTo explore the efficacy of large trauma craniotomy with bilateral frontal coronal incision in treating contusion and laceration of bilateral frontal lobes.MethodsThe clinical data of 68 patients with contusion and laceration of bilateral frontal lobes who were treated with bilateral decompressive craniectomy were analyzed retrospectively.There were 36 cases(observation group) treated with large trauma craniotomy with bilateral frontal coronal incision and 32 cases (control group) given bilateral decompressive craniectomy by stages.The prognosis of two groups were observed and compared.The prognosis was evaluated at 6 months after surgery by Glasgow outcome scale (GOS) score.ResultsThere were 23 cases (63.89％,23/36) who got good recovery,8 cases(22.22％,8/36) with poor prognosis and 5 dead cases (13.89％,5/36) in observation group.There were 11 cases (34.38％,11/32) who got good recovery,9 cases (28.12％,9/32) with poor prognosis and 12 dead cases (37.50％,12/32) in control group.The rate of good recovery and mortality between two groups had significant differences (P ＜ 0.05).ConclusionsThe large trauma craniotomy with bilateral frontal coronal incision can significantly relieve or ease intracranial hypertension of patients with contusion and laceration of bilateral frontal lobes.And it can improve the prognosis and decrease the mortality.

Objective To investigate the protective effect of astragaloside on cardiomyocyte mitochoddria and inhibition effect on cardiomyocytes apoptosis of the rats with heart failure, and explore the treatment mechanism. Methods Sixty SD rats were randomly divided into control group, model group, astragaloside group, and trimetazidine group. The last three groups were injected subcutaneously with isoproterenol to make the heart failure model. Astragaloside group was given astragaloside 50 mg/(kg?d), and trimetazidine group was given trimetazidine 10 mg/(kg?d) orally for three consecutive weeks. At the end of the experiment, the myocardial tissue specimens of each group were made, inverted fluorescence microscope was utilized for measuring mitochondrial membrane potential (MMP), immunoblotting was utilized for detecting cardiomyocyte telomerase reverse transcriptase (TERT) expression, and flow cytometry was untilized for detecting cardiomyocyte apoptosis. Results The MMP ratio of astragaloside group was 3.226±0.371, significantly higher than the model group and trimetazidine group (P<0.01). The cardiomyocyte apoptosis rate of astragaloside group was 8.91±2.12, significantly lower than the model group and trimetazidine group (P<0.01), and the most obvious expression of TERT was found in astragaloside group. Conclusion Astragaloside can protect damaged mitochondria, promote TERT expression, inhibit cardiomyocyte apoptosis and protect cardiomyocytes.